Why Oncorus Stock Is Crashing Today

Shares of Oncorus (NASDAQ: ONCR) were crashing 44.7% lower at 11:11 a.m. EST on Friday. The big decline came after the drugmaker announced initial data from its ongoing phase 1 clinical study evaluating experimental immunotherapy ONCR-177 in treating patients with solid tumors.

Oncorus reported that ONCR-177 was well tolerated. It said that there were no dose-limiting toxicities in heavily pretreated patients with surface lesions who were part of the dose-escalation part of the study.

The company also referred to the initial clinical response data as "positive." Oncorus said that three of eight evaluable patients experienced clinical benefit after receiving two doses of ONCR-177.

Continue reading

Source Fool.com